Eli Lilly and Company has unveiled an ambitious plan to invest more than USD 1 billion in new contract manufacturing operations in India over the next several years marking one of the company’s largest commitments in the region. The investment aims to enhance Lilly’s global manufacturing and supply chain network, ensuring greater access to its portfolio of innovative medicines.
As part of the initiative, the company will also establish a Manufacturing & Quality (M&Q) hub in Hyderabad, which will serve as a centre for advanced technical expertise and oversight of Lilly’s contract manufacturing partners across India. Recruitment for the new hub has already begun, with roles open for engineers, chemists, analytical scientists, and quality professionals, among others.
Welcoming the announcement, Telangana Chief Minister A. Revanth Reddy said Lilly’s decision further cements Hyderabad’s position as a global healthcare innovation hub. “From its Innovation and Technology site to this new manufacturing collaboration and M&Q hub, Lilly’s continued expansion reflects Hyderabad’s growing stature as a preferred destination for advanced healthcare investments,” he said.
Echoing this sentiment, Sridhar Babu, Minister for IT, Industries, and Commerce, noted that the company’s expansion highlights Telangana’s strong industrial ecosystem. “Our focus on technology-led infrastructure and ease of doing business has made Telangana a magnet for global healthcare and life sciences leaders,” he added.
Nivruti Rai, Managing Director & CEO of Invest India, described the investment as a reflection of India’s emergence as a competitive global manufacturing and innovation hub. “Lilly’s commitment underscores confidence in India’s skilled talent pool, strong infrastructure, and business-friendly environment,” she said. “Together, we are shaping a stronger future for healthcare and manufacturing.”
Patrik Jonsson, Executive Vice President and President of Lilly International, said the company’s global investments are focused on expanding manufacturing and medicine supply capabilities. “Collaborating with trusted contract manufacturers allows us to deliver life-changing medicines at scale, without compromising on quality,” he said. “Our investment in India reinforces our confidence in the country’s capabilities and its vital role within Lilly’s global network.”
With this latest move, Eli Lilly deepens its footprint in India, leveraging the country’s growing prominence in life sciences and bio pharmaceutical manufacturing while contributing to its mission of improving global access to high-quality medicines.
